Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jessica Merrill

New York, NY
Jessica Merrill is a Bureau Editor for US Commercial Content for Informa’s pharmaceutical news publications, including “The Pink Sheet” and SCRIP. She has been covering the pharmaceutical industry as a journalist for more than 10 years, spanning the spectrum from R&D to regulatory to commercial. She was previously a reporter and editor for “The Pink Sheet” and “Pink Sheet” DAILY, specializing in business and commercial news, focusing largely on big pharma, M&A and business development, and the commercial landscape, including drug launches and market access. Before embarking on a career in healthcare journalism, she covered business news for the cosmetics industry and worked as a newspaper reporter.

Latest From Jessica Merrill

Tecfidera Headwinds Could Mean Cuts At Biogen, Unless Aducanumab Succeeds

Biogen lowered revenue guidance for the year by $600m due to Tecfidera generics and said it could consider broader cost cuts in 2021 depending on the outcome of aducanumab at the US FDA.

Business Strategies Sales & Earnings

Regeneron's Inmazeb Approval For Ebola Paves The Way In COVID-19

The US FDA approved the first antibody cocktail for ebolavirus infection, supporting a supply contract with BARDA. The development experience informed Regeneron's work in COVID-19.

Infectious Diseases Approvals

Revance Builds Therapeutics Credibility For DaxibotulinumtoxinA Ahead Of Aesthetics Launch

The long-acting neuromodulator improved symptoms of cervical dystonia in a Phase III trial with longer duration of efficacy versus older products; a launch for aesthetics is expected soon.  

Clinical Trials Business Strategies

J&J Says It's Wait And See On COVID-19 Vaccine Delay, Outlines Rosier Outlook for 2021

It will be several days at least before more information is available about the unexpected illness in J&J's Phase III COVID-19 vaccine trial, the firm said during its third quarter financial call.

Sales & Earnings Coronavirus COVID-19

Mallinckrodt Finalizes Bankruptcy Filing And Opioid, Acthar Settlements

The company will pay $1.6bn to settle opioid litigation and $260m to settle a Medicaid rebate dispute related to Acthar Gel under a restructuring support agreement.

Legal Issues Financing

Jazz Phase III Success With Xywav In Idiopathic Hypersomnia Strengthens A Valuable Franchise

The company plans to file for approval in the expanded indication, for which there are currently no approved therapies.

Business Strategies Neurology
See All
UsernamePublicRestriction

Register